These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30393149)

  • 21. Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIX™ adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaques.
    DiStefano D; Antonello JM; Bett AJ; Medi MB; Casimiro DR; ter Meulen J
    Vaccine; 2013 Oct; 31(42):4888-93. PubMed ID: 23941913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment of a potency test by ELISA for a rabies vaccine for animal use in Japan.
    Gamoh K; Shimazaki Y; Senda M; Makie H; Itoh O; Muramatsu M; Hirayama N; Hatakeyama H
    J Vet Med Sci; 2003 Jun; 65(6):685-8. PubMed ID: 12867727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulatory acceptance and use of serology for inactivated veterinary rabies vaccines.
    Schiffelers MJ; Blaauboer BJ; Bakker WE; Hendriksen CF
    ALTEX; 2015; 32(3):211-21. PubMed ID: 25936354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of animal suffering in rabies vaccine potency testing by introduction of humane endpoints.
    Takayama-Ito M; Lim CK; Nakamichi K; Kakiuchi S; Horiya M; Posadas-Herrera G; Kurane I; Saijo M
    Biologicals; 2017 Mar; 46():38-45. PubMed ID: 28040390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis.
    Wongsaroj P; Udomchaisakul P; Tepsumethanon S; Khawplod P; Tantawichien T
    Vaccine; 2013 Mar; 31(13):1748-51. PubMed ID: 23370149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of SURE RAB™, an inactivated cell culture derived rabies vaccine: A comparative, phase III clinical trial.
    Kakar A; Gogia A; Solanki SK; Jadiya A; Singh D
    Indian J Med Microbiol; 2021 Jan; 39(1):63-66. PubMed ID: 33526271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of immunogenicity, efficacy and transcriptome changes of inactivated rabies virus vaccine with different adjuvants.
    Shi W; Kou Y; Xiao J; Zhang L; Gao F; Kong W; Su W; Jiang C; Zhang Y
    Vaccine; 2018 Aug; 36(33):5020-5029. PubMed ID: 30037417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid fluorescent focus inhibition test optimization and validation: Improved detection of neutralizing antibodies to rabies virus.
    Timiryasova TM; Luo P; Zheng L; Singer A; Zedar R; Garg S; Petit C; Moore S; Hu BT; Brown M
    J Immunol Methods; 2019 Nov; 474():112626. PubMed ID: 31228423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines.
    Rooijakkers E; Groen J; Uittenbogarrd J; van Herwijnen J; Osterhaus A
    Dev Biol Stand; 1996; 86():137-45. PubMed ID: 8785943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preexposure efficacy of a novel combination DNA and inactivated rabies virus vaccine.
    Biswas S; Reddy GS; Srinivasan VA; Rangarajan PN
    Hum Gene Ther; 2001 Oct; 12(15):1917-22. PubMed ID: 11589833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults.
    Ma J; Wang H; Li J; Chang L; Xie Y; Liu Z; Zhao Y; Malerczyk C
    Hum Vaccin Immunother; 2014; 10(10):2805-12. PubMed ID: 25483635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative study on the safety and immunogenicity of Purified duck embryo vaccine [corrected] (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purifed vero cell rabies vaccine (PVRV, Verorab).
    Ashwathnarayana DH; Madhusudana SN; Sampath G; Sathpathy DM; Mankeshwar R; Ravish HH; Ullas PT; Behra TR; Sudarshan MK; Gangaboraiah ; Shamanna M
    Vaccine; 2009 Dec; 28(1):148-51. PubMed ID: 19818720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rabies pre-exposure prophylaxis elicits long-lasting immunity in humans.
    Mansfield KL; Andrews N; Goharriz H; Goddard T; McElhinney LM; Brown KE; Fooks AR
    Vaccine; 2016 Nov; 34(48):5959-5967. PubMed ID: 27997343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of PVRV and HDCV rabies vaccines as to immunity, reliability and protective value].
    Hacibektaşoğlu A; Inal A; Eyigün C; Barut A; Türkay FA
    Mikrobiyol Bul; 1992 Jan; 26(1):26-36. PubMed ID: 1574019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetically modified rabies virus-vectored Ebola virus disease vaccines are safe and induce efficacious immune responses in mice and dogs.
    Shuai L; Wang X; Wen Z; Ge J; Wang J; Zhao D; Bu Z
    Antiviral Res; 2017 Oct; 146():36-44. PubMed ID: 28822816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine.
    Nunberg JH; Doyle MV; York SM; York CJ
    Proc Natl Acad Sci U S A; 1989 Jun; 86(11):4240-3. PubMed ID: 2786210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In Vitro ELISA Test to Evaluate Rabies Vaccine Potency.
    Jallet C; Tordo N
    J Vis Exp; 2020 May; (159):. PubMed ID: 32449742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A relevant in vitro ELISA test in alternative to the in vivo NIH test for human rabies vaccine batch release.
    Gibert R; Alberti M; Poirier B; Jallet C; Tordo N; Morgeaux S
    Vaccine; 2013 Dec; 31(50):6022-9. PubMed ID: 24161572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and evaluation of a competitive ELISA for estimation of rabies neutralizing antibodies after post-exposure rabies vaccination in humans.
    Muhamuda K; Madhusudana SN; Ravi V
    Int J Infect Dis; 2007 Sep; 11(5):441-5. PubMed ID: 17321182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potency evaluation of rabies vaccine for human use: The impact of reducing the number of animals per dilution - Part 2.
    Machado NS; Moreira WC; Freitas JFS; Almeida AECC; Moura WC
    Biologicals; 2020 Jul; 66():30-34. PubMed ID: 32448736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.